Navigation Links
Large genomic study identifies endometrial cancer subtypes, treatment opportunities
Date:5/1/2013

NEW YORK, MAY 1, 2013 Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan-Kettering Cancer Center and other centers within The Cancer Genome Atlas (TCGA) Research Network.

Published in the May 2 issue of the journal Nature, the findings may help doctors more accurately diagnose endometrial cancer and choose treatments that will target genomic mutations in women with endometrioid and uterine serous adenocarcinomas, the two most common types of endometrial cancer. The findings could also guide clinical trials and the development of new drugs.

"These findings have an immediate therapeutic application, as patients with endometrial cancer can be tested routinely to see whether they qualify for a targeted therapy clinical trial," said Memorial Sloan-Kettering gynecologic oncologist Douglas A. Levine, MD, corresponding author on the study, principal investigator of Memorial Sloan-Kettering's TCGA Tissue Source Site, and Co-Chair of TCGA's Endometrial Working Group. "The current landscape of treatment for endometrial cancer is quite chaotic, and this research may provide order to that landscape, especially for more-aggressive endometrial cancers."

Endometrial cancer, which forms in the tissues lining the uterus, is the fourth leading type of cancer among women and the eighth leading cause of cancer death. Endometrioid tumors are usually less aggressive, while uterine serous tumors are more aggressive.

There has been little agreement among doctors over the best treatment approach following surgery for patients with a high risk of recurrence, with decisions relying largely on a tumor's pathology. However, it is difficult for pathologists to reliably differentiate high-grade endometrioid tumors from uterine serous tumors.

According to Dr. Levine, incorporating new genomic information into treatment planning could be a great leap forward, helping to make certain that additional therapies are used effectively and only when necessary.

The analysis of 373 endometrial tumors showed that approximately a quarter of high-grade endometrioid tumors have certain types of genomic alterations also found in uterine serous tumors. This suggests that a significant portion of endometrioid tumors should be treated more aggressively after surgery.

Many of the tumors analyzed had mutations in important cancer-related genes and pathways for which targeted therapies are already being tested in clinical trials for other cancers. For example, 84 percent of the tumors have some alteration in the PI3 kinase pathway, which is implicated in many cancers. Additionally, genomic alterations in uterine serous tumors share many features with ovarian serous and triple-negative breast cancers, suggesting opportunity for shared treatments.

Investigators at Memorial Sloan-Kettering are now translating these findings into clinically useful tests that may be applied to ongoing and planned clinical trials.

A project jointly funded by the National Cancer Institute and the National Human Genome Research Institute, TCGA is one of the most comprehensive national efforts to collect and analyze the largest set of tumor samples to date using state-of-the-art genomic and molecular techniques. Memorial Sloan-Kettering currently houses one of TCGA's Genome Data Analysis Centers, led by computational biologist Chris Sander, PhD, biocomputing manager Nikolaus Schultz, PhD, and molecular pathologist Marc Ladanyi, MD. For the endometrial cancer study, Memorial Sloan-Kettering contributed more than 10 percent of all tissue samples analyzed.


'/>"/>

Contact: Caitlin Hool
hoolc@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. BroadConnect Telecom Now Has the Largest Ethernet over Copper Footprint in the Nation As Result of Completion of National EoC Rollout
2. Princeton Ivy Capital Advisors LLC Receives #1 Rank According to Money Manager Review (MMR is an Independent Third Party Ranking Authority) for Large Cap Core Managers
3. Nation’s Largest Healthy Vending Company Announces Its Continued Growth
4. New Procedure May Shrink Enlarged Prostate Without Surgery
5. Registration opens for Asia-Pacifics largest medical conference on osteoporosis
6. Teen Boys With Enlarged Breasts Show Emotional Effects
7. Ms. Viola Richardson, Jersey City Councilwoman-at-Large, Participates in the Annual Steve Sobel SYC 2013 Fencing Competition
8. Picky Eating in Youngsters Might Be Largely Caused by Genes
9. People With Mental Illness Make Up Large Share of U.S Smokers
10. On March 1, 2013 SBSI Training & Development Solutions Went into Operations Providing Training and Development Solutions to Midsized and Large Organizations
11. Large study finds that physician gender does not affect patient-care costs or mortality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Finally, a bruise ... venous procedures, dermaka cream can be incorporated into the post-surgical treatment plans of a ... procedures. , dermaka cream is very effective for bruising and causes a rapid ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology: